Back to News
Medication Withdrawals
February 28, 2020
The FDA announced the request to voluntarily withdraw Belviq, Belviq XR (lorcaserin) from the U.S. market because a safety clinical trial showed an increased occurrence of cancer. Eisai, the manufacturer, has submitted a request to voluntarily withdraw the drug.
Clinical Services will be conducting a drug recall mailing to potentially impacted members and providers.
| Property | Value |
|---|---|
| Products | Belviq, Belviq XR |
| Manufacturer | Eisai |
| Withdrawal identification date | 02/13/2020 |
| Affected NDCs | 62856-0529-60, 62856-0535-30 |
| Look back period | 10/16/2019 - 2/13/2020 |
| Target population for clinical mailing | All |
| Mailing type | Members and Providers |
| Data release | SS00005114 |
| Fulfillment due date for NCQA compliance | On or before: 3/4/2020 |